EF-CAB9 Inhibitors
EF-CAB9 inhibitors are a class of chemical compounds that specifically target and modulate the activity of EF-CAB9, a protein belonging to the EF-hand calcium-binding protein family. EF-CAB9 is characterized by the presence of EF-hand motifs, which are helix-loop-helix structural domains that coordinate the binding of calcium ions. Calcium binding to EF-CAB9 induces conformational changes in the protein, enabling it to interact with a variety of cellular targets. These interactions are critical for the regulation of intracellular calcium signaling pathways, which play a pivotal role in numerous cellular processes, including gene expression, enzyme activation, muscle contraction, and cell division. EF-CAB9 is thought to be involved in the fine-tuning of these processes, acting as a mediator that translates calcium fluctuations into specific cellular responses.
Inhibitors of EF-CAB9 function by interfering with its calcium-binding capacity or by disrupting its interactions with other proteins within the cell. These inhibitors might bind directly to the EF-hand motifs of EF-CAB9, blocking calcium from binding and thereby preventing the necessary conformational changes that enable its activity. Alternatively, some inhibitors may induce conformational changes in EF-CAB9 that hinder its ability to interact with downstream target proteins, effectively modulating the signaling pathways that depend on EF-CAB9's activity. By inhibiting EF-CAB9, these compounds provide researchers with tools to investigate the specific roles this protein plays in cellular calcium signaling and its broader impact on cellular functions. The study of EF-CAB9 inhibitors allows for a deeper understanding of the intricate mechanisms by which calcium signals are transduced within cells, shedding light on the complex regulatory networks that maintain cellular homeostasis and respond to various physiological stimuli.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent kinase inhibitor that indirectly inhibits EF-CAB9 by targeting a broad range of kinases within the signaling pathways EF-CAB9 is involved in, leading to reduced EF-CAB9 phosphorylation and subsequent activity. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
As a specific inhibitor of protein kinase C (PKC), Bisindolylmaleimide I disrupts PKC-mediated signal transduction processes, which indirectly results in the inhibition of EF-CAB9 if PKC phosphorylation is required for its activation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is an inhibitor of phosphoinositide 3-kinases (PI3K), and by inhibiting PI3K, it impairs the PI3K/AKT signaling pathway, thereby possibly reducing the activation state of EF-CAB9 if it is downstream of AKT. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002, a PI3K inhibitor, also impairs the PI3K/AKT pathway, leading to decreased phosphorylation and activity of downstream proteins, potentially including EF-CAB9. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
By selectively inhibiting MEK1/2, PD 98059 can inhibit the MAPK/ERK pathway, leading to reduced activity of downstream proteins such as EF-CAB9 if it is regulated by ERK phosphorylation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and inhibits mTOR, which is a central regulator of cell growth and metabolism. This inhibition can lead to reduced activity of downstream proteins including EF-CAB9 if it is part of the mTOR signaling pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2 and thereby inhibits the MAPK/ERK pathway, which could indirectly result in decreased activity of EF-CAB9 if it is an ERK pathway component. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
This compound inhibits p38 MAP kinase, which could lead to the inhibition of EF-CAB9 if it is regulated via stress-activated protein kinase pathways that involve p38 MAPK. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which impairs JNK signaling and could lead to the inhibition of EF-CAB9 if it is regulated by JNK-mediated phosphorylation. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine is an AKT inhibitor, which prevents the phosphorylation and activation of AKT targets, potentially reducing the activity of EF-CAB9 if it is an AKT substrate. | ||||||